Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth

Journal of Investigative Dermatology

Volumn 133, Issue 2, 2013, Pages 499-508

  Hervieu, Alice ^a,b,c,d   Rébé, Cédric ^a,b,c   Végran, Frédérique ^a,b   Chalmin, Fanny ^a,b   Bruchard, Mélanie ^a,b   Vabres, Pierre ^d   Apetoh, Lionel ^a,b,c   Ghiringhelli, François ^a,b,c   Mignot, Grégoire ^a,b  

^a Chu   (France)

^b INSERM   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DOXORUBICIN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION; WILD TYPE;

EID: 84872616881     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.273     Document Type: Article

References (44)

1. Apetoh L, Ghiringhelli F, Tesniere A et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-9
2. Apetoh L, Mignot G, Panaretakis T et al. (2008) Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 14:141-51
3. Apetoh L, Vegran F, Ladoire S et al. (2011) Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med 11:365-72
4. Casado JG, Pawelec G, Morgado S et al. (2009) Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 58:1517-26
5. Cerwenka A, Bakker AB, McClanahan T et al. (2000) Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12:721-7
6. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521-6
7. Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235:267-85
8. Diefenbach A, Jamieson AM, Liu SD et al. (2000) Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119-26
9. Diefenbach A, Jensen ER, Jamieson AM et al. (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-71
10. Dranoff G (2011) Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol 12:61-6
11. Fine JH, Chen P, Mesci A et al. (2010) Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res 70:7102-13
12. Fregni G, Perier A, Pittari G et al. (2011) Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 17:2628-37
13. Gannage M, Buzyn A, Bogiatzi SI et al. (2008) Induction of NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may participate in the tissue damage during acute graft-versus-host disease. Transplantation 85:911-5
14. Gasser S, Orsulic S, Brown EJ et al. (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:1186-90
15. Gerner RE, Moore GE, Dickey C (1975) Combination chemotherapy in disseminated melanoma and other solid tumors in adults. Oncology 31:22-30
16. Ghiringhelli F, Apetoh L, Tesniere A et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170-8
17. Ghiringhelli F, Larmonier N, Schmitt E et al. (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-44
18. Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23
19. Kadison AS, Morton DL (2003) Immunotherapy of malignant melanoma. Surg Clin North Am 83:343-70
20. Kaplan MG (2011) Ipilimumab plus dacarbazine in melanoma. N Engl J Med 365:1256-7; author reply 7-8
21. Kim JY, Son YO, Park SW et al. (2006) Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 38:474-84
22. Lugade AA, Sorensen EW, Gerber SA et al. (2008) Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180:3132-9
23. Lui P, Cashin R, Machado M et al. (2007) Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33:665-80
24. Mistry AR, O'Callaghan CA (2007) Regulation of ligands for the activating receptor NKG2D. Immunology 121:439-47
25. Nice TJ, Deng W, Coscoy L et al. (2010) Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase. J Immunol 185:5369-76
26. Obeid M, Tesniere A, Ghiringhelli F et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61
27. Palermo B, Del Bello D, Sottini A et al. (2010) Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res 70:7084-92
28. Paschen A, Sucker A, Hill B et al. (2009) Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15:5208-15
29. Pende D, Cantoni C, Rivera P et al. (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31:1076-86
30. Pietra G, Manzini C, Rivara S et al. (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72:1407-15
31. Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14:848-61
32. Robert C, Thomas L, Bondarenko I et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-26
33. Salih HR, Holdenrieder S, Steinle A (2008) Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 13:3448-56
34. Soriani A, Zingoni A, Cerboni C et al. (2009) ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113:3503-11
35. Sutherland CL, Rabinovich B, Chalupny NJ et al. (2006) ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108:1313-9
36. Suzuki E, Kapoor V, Jassar AS et al. (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713-21
37. Tanaka H, Matsushima H, Nishibu A et al. (2009) Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 69:6987-94
38. Tarhini AA, Iqbal F (2010) CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 3:15-25
39. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and meta-static tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-66
40. Vincent J, Mignot G, Chalmin F et al. (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70:3052-61
41. Walker LS, Sansom DM (2011) The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11:852-63
42. Zhang T, Sentman CL (2011) Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 71:2066-76
43. Zitvogel L, Apetoh L, Ghiringhelli F et al. (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73
44. Zoller M, Strubel A, Hammerling G et al. (1988) Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread. Int J Cancer 41:256-66